Traditionally, the genetic screening strategy for FH has been Sanger sequencing for assessment of all coding regions in LDLR plus one or two specific exons in APOB, followed by multiplex ligation-dependent probe amplification (MLPA) for detection of CNVs in LDLR (13). The gene discussed is LDLR; the disease is familial hyperaldosteronism.